Last reviewed · How we verify
NCT04123535: HIFU-UPS
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
NA trial testing ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) in Undifferentiated Pleomorphic Sarcoma in 20 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Matthew Bucknor |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 23 January 2020 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Conditions studied
- Undifferentiated Pleomorphic Sarcoma — all drugs for Undifferentiated Pleomorphic Sarcoma →
Sponsor
Matthew Bucknor
Who can join
18 and older, any sex, with Undifferentiated Pleomorphic Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablation of undifferentiated pleomorphic sarcomas.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunomodulation and targeted drug delivery with high intensity focused ultrasound (HIFU): Principles and mechanisms.
Ashar H, Ranjan A. · · 2023 · cited 41× · PMID 36965581 · DOI 10.1016/j.pharmthera.2023.108393 -
Overview of Therapeutic Ultrasound Applications and Safety Considerations: 2024 Update.
Bader KB, Padilla F, Haworth KJ, Ellens N, et al · · 2025 · cited 23× · PMID 39526313 · DOI 10.1002/jum.16611 -
The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study.
Liu Z, Wang X, Wang J, Zhang P, et al · · 2023 · cited 8× · PMID 36910639 · DOI 10.3389/fonc.2023.1124517 -
Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment.
Fang T, Xiao J, Zhang Y, Hu H, et al · · 2021 · cited 8× · PMID 34079746 · DOI 10.21037/qims-20-173 -
Guidelines for immunological analyses following focused ultrasound treatment.
Padilla F, Foley J, Timbie K, Bullock TNJ, et al · · 2023 · cited 2× · PMID 38007236 · DOI 10.1136/jitc-2023-007455 -
The Thermal Ablation with MRgFUS: From Physics to Oncological Applications.
Leporace M, Calabria FF, Siciliano R, Capalbo C, et al · · 2024 · cited 1× · PMID 39796667 · DOI 10.3390/cancers17010036 -
Focused Ultrasound for Sarcomas: A Narrative Review.
Kuchimanchi N, Sul N, Gajula S, Mercante M, et al · · 2025 · PMID 40862821 · DOI 10.3390/curroncol32080452
Verify or expand the search:
- PubMed search for NCT04123535
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Undifferentiated Pleomorphic Sarcoma
Currently open trials in the same condition.
- NCT04420975 — Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma · Phase 1 · active not recruiting
- NCT04332874 — A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm · Phase 2 · recruiting
- NCT04055220 — Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas · NA · recruiting
- NCT02923778 — Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be · Phase 2 · active not recruiting
- NCT03307616 — Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferen · Phase 2 · active not recruiting
Other Matthew Bucknor trials
Trials by the same sponsor.
- NCT02923011 — Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04123535 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Matthew Bucknor
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04123535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing